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OBJECTIVES The goal of this study was to investigate plasma levels of myotrophin in heart failure (HF) and
their relationship to gender and disease severity.
BACKGROUND Myotrophin is a myocardial hypertrophy-inducing factor initially demonstrated in hypertro-
phied and cardiomyopathic hearts. Recent evidence suggests an interaction with the
transcription factor nuclear factor kappa B (NFB), which is activated in HF and modulates
myocardial protein expression. It is unknown whether this peptide has an endocrine/paracrine
role in man. We hypothesized that it may have a role in HF and would be raised in plasma.
METHODS We developed a competitive binding assay specific for human myotrophin. Myotrophin was
measured in plasma extracts of 120 HF patients and 130 age- and gender-matched normal
controls.
RESULTS Myotrophin in plasma existed as the full-length 12 kD form with also a 2.7 kD form (possibly
a degradation product). Log normalized myotrophin levels were significantly elevated in HF
patients (mean  SEM [geometric mean, range], 2.402  0.021 [252, 72 to 933] vs. 2.268
 0.021 [185, 28 to 501] fmol/ml, p  0.0005). There was no relationship between
myotrophin and age or gender in controls. However, males with HF had higher levels of
myotrophin than females (p 0.001). There was an inverse relationship of myotrophin levels
with New York Heart Association class in patients with no gender difference in the
relationship.
CONCLUSIONS There is evidence of early activation of the myotrophin system in HF, which is more evident
in males. This response is attenuated in more severe disease. The contribution of myotrophin
to NFB-mediated gene transcription and preservation of cardiac muscle mass remains to be
investigated further. (J Am Coll Cardiol 2003;42:719–25) © 2003 by the American
College of Cardiology Foundation
A number of endocrine and paracrine systems are activated
in human heart failure (HF). These include the renin-
angiotensin system, catecholamines, endothelin, the natri-
uretic peptides, and cytokines such as tumor necrosis factor-
alpha (TNF). In the early stages of HF, activation of some
of these systems may serve to compensate for the reduced
cardiac output, but, as the disease progresses, they may
contribute to deterioration by affecting left ventricular (LV)
remodeling.
See page 726
Myotrophin is a 12 kD protein initially isolated from
hypertrophied hearts of spontaneously hypertensive rats (1).
Subsequently, levels were found to be elevated in human
cardiomyopathic hearts (2). In vitro, its effects on cultured
cardiomyocytes include an increase in protein synthesis,
cellular hypertrophy, gap-junction formation, increased sar-
comere number, induction of early response genes such as
c-myc, c-fos, c-jun, and, subsequently, of transcripts of
skeletal -actin, total myosin, and atrial natriuretic peptide
(3). The hypertrophic effects on cardiomyocytes are medi-
ated via protein kinase C activation (4). Due to the presence
of tandem ankyrin repeats in the myotrophin molecule and
their resemblance to those found in the IB/rel proteins, a
role has been postulated for myotrophin binding to and
modulating activity of the transcription factor nuclear factor
kappa B (NFB) (5). Recent evidence suggests that myotro-
phin disrupts the formation of the NFB p50-p65 transac-
tivating heterodimers while increasing the formation of
repressive NFB p50-p50 homodimers (6). Cyclic stretch
leads to increased myotrophin levels in cardiomyocytes with
increased translocation of the factor into the nucleus from
the cytoplasm (7). Myotrophin and TNF increase the
expression of each other in cardiomyocytes (7). There is
evidence of increased activity of NFB in human HF, with
a role postulated for induction of a number of inflammatory
mediators (8,9).
Human myotrophin was cloned recently and found to be
highly homologous to the rat protein (10). Its messenger
ribonucleic acid (mRNA) is widely distributed in many
tissues, with relatively high levels in heart, skeletal muscle,
liver, and pancreas. In the cardiovascular system, myotro-
phin mRNA was expressed in monocytes, macrophages,
vascular smooth muscle, and endothelial cells. The recom-
binant myotrophin protein stimulates protein synthesis, and
increased mRNA was found in a small number of heart
specimens with dilated or ischemic cardiomyopathy (10).
To date, there has been no report of the presence of this
peptide in human plasma and its levels in patients with HF.
In view of its potential role in modulating NFB activity,
and the documented role of this transcription factor in HF,
we investigated the myotrophin system in humans with HF.
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Although present within cells, extracellular myotrophin has
effects on protein synthesis, cell hypertrophy, and induction
of early genes, which may point to other effects of this
peptide (3,4,7).
METHODS
Study populations. We studied 120 HF patients, all with
echocardiographically confirmed LV systolic dysfunction
(LV ejection fraction 45%). Age- and gender-matched
normal controls, LV ejection fraction 50%, were recruited
from the local community by advertisement. All subjects
gave informed consent to participate in the study, which was
approved by the local ethics committee. The study conforms
to the principles of the Declaration of Helsinki.
Blood sampling and plasma extraction. A total of 20 ml
of peripheral venous blood was drawn into pre-chilled
Na-EDTA (1.5mg/ml blood) tubes containing 500 IU/ml
aprotinin. After centrifugation at 3,000 rpm at 4°C for
15 min, plasma was separated and stored at 70°C until
assay. Prior to assay, plasma was extracted on C18
Sep-Pak (Waters, Peninsular Labs, Liverpool, United
Kingdom) columns and dried on a centrifugal evaporator.
Assay of myotrophin. A peptide corresponding to a
C-terminal domain (amino acids 102-113) of the human
myotrophin sequence (LTAFEATDNQAI) (10) was syn-
thesized in the Medical Research Council Toxicology Unit,
University of Leicester. A rabbit was injected monthly with
this peptide conjugated to keyhole limpet hemocyanin as
previously described (11); IgG from the sera was purified on
protein A sepharose columns. The above peptide was also
biotinylated using biotin-X-N-hydroxysuccinimide ester
(Calbiochem, Nottingham, United Kingdom) and the
tracer purified on HPLC using an acetonitrile gradient.
Plasma extracts and standards were reconstituted with
immunoluminometric assay (ILMA) buffer consisting of (in
mmol/l) NaH2PO4 1.5, Na2HPO4 8, NaCl 140, EDTA 1,
and (in g/l) bovine serum albumin 1, azide 0.1; ELISA
plates were coated with 100 ng of anti-rabbit IgG (Sigma
Chemical Co., Poole, United Kingdom) in 100 l of 0.1
mol/l sodium bicarbonate buffer, pH 9.6. Wells were then
blocked with 0.5% bovine serum albumin in bicarbonate
buffer. A competitive immunoluminometric assay was set up
by preincubating 50 ng of the IgG with standards or
samples within the wells. After overnight incubation, 50 l
of the diluted biotinylated myotrophin peptide tracer (1
l/ml of the stock solution) was added to the wells. After
another 24 h of incubation at 4°C, wells were washed three
times with a wash buffer (NaH2PO4 1.5 mmol/l, Na2HPO4
8 mmol/l, NaCl 340 mmol/l, Tween 0.5 g/l, sodium azide
0.1 g/l). Streptavidin labeled with methyl-acridinium ester
(MAE) was synthesized as described (12). Wells were
incubated for 2 h with 100 l of ILMA containing
streptavidin-MAE (5 million relative light units per well).
After further washes, chemiluminescence was detected by
sequential injections of 100 l of 0.1 M nitric acid (with
H2O2) and then 100 l of NaOH (with cetyl ammonium
bromide) (11,12) in a Dynatech MLX Luminometer
(Dynex Technologies Inc., Worthing, West Sussex, United
Kingdom). The lower limit of detection was 11.6 fmol/ml.
Within and between assay coefficients of variation were
3.5% and 7%, respectively. There was no cross-reactivity
with peptides previously demonstrated to be elevated in HF
such as atrial natriuretic peptide, brain natriuretic peptide,
N-terminal pro-brain natriuretic peptide, C-type natriuretic
peptide, cardiotrophin-1, or leukemia inhibitory factor.
Size exclusion chromatography and gel electrophoresis of
plasma extracts. Plasma extracts were fractionated by iso-
cratic size exclusion chromatography on a 300  7.8 mm
Bio-Sep SEC S2000 column (Phenomenex, Macclesfield,
Cheshire, United Kingdom) using 50 mmol/l NaH2PO4
(pH 6.8) at a flow rate of 1 ml/min as the mobile phase.
Standards used to establish molecular weights included IgG
(150 kD), bovine serum albumin (68 kD), ovalbumin (44
kD), soybean trypsin inhibitor (20 kD), aprotinin (6.5 kD),
and tryptophan (204D) (Sigma Chemical Co.). Fractions
collected every 20 s were dried on a centrifugal evaporator
before assaying for myotrophin as preceding text.
A total of 50 g of rat tissue extracts (heart, brain,
muscle, liver, kidney, spleen) were also resolved on 17%
SDS polyacrylamide gels with colored molecular weight
markers, with subsequent blotting of the proteins onto
reinforced nitrocellulose (0.2 mm). Blots were blocked
overnight in 1% dried low-fat milk powder in Tris buffered
saline (TBS, composed of Tris 20 mmol/l, NaCl 135
mmol/l) containing 0.1% Tween-20. Detection was per-
formed with the myotrophin antibody (1 g/ml in TBS
Tween) for 2 h at room temperature, followed by donkey
anti-rabbit IgG horseradish peroxidase conjugate (Amer-
sham, United Kingdom). The bands were visualized using
enhanced chemiluminescence kits (Amersham, United
Kingdom) onto pre-flashed X-ray films.
Human leucocytes were also fixed on glass slides with 2%
paraformaldehyde in phosphate buffered saline for 20 min,
before permeabilizing with 0.2% Triton X-100 for 15 min
(7). Endogenous peroxidases were blocked by treatment
with 0.5% H2O2 for 10 min. After blocking with 10% goat
serum overnight, slides were incubated in 10 g/ml myotro-
Abbreviations and Acronyms
HF  heart failure
ILMA  immunoluminometric assay
LV  left ventricle/ventricular
mRNA  messenger ribonucleic acid
NFB  nuclear factor kappa B
NYHA  New York Heart Association
streptavidin-MAE  streptavidin labeled with methyl-
acridinium ester
TNF  tumor necrosis factor-alpha
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phin antibody in phosphate buffered saline Tween over-
night. Control slides were not incubated with the myotro-
phin antibody. After extensive washes, detection was with
donkey anti-rabbit IgG horseradish peroxidase conjugate
(1:1,000) and visualized using 3, 3-diaminobenzidene.
Statistical analysis. Statistical analysis was performed us-
ing SPSS Version 11.0 (SPSS Inc., Chicago, Illinois). Data
are presented as mean  SEM or median (range) for data
with non-Gaussian distribution, which were log-
transformed before analysis. Normality of distribution
of data was confirmed by the Anderson-Darling test.
For continuous variables, one-way analysis of variance
(ANOVA) was used. The interaction of multiple inde-
pendent variables was sought using the univariate general
linear model procedure with p values from Bonferonni’s test
reported. Pearson correlation analysis was performed, and
box plots were constructed consisting of medians, boxes
representing interquartile ranges, and the whiskers repre-
senting the 2.5th to the 97.5th percentile. A p value below
0.05 was considered statistically significant.
Figure 1. A standard curve for the myotrophin competitive immunoassay. A patient’s plasma extract (solid circles joined by dotted line) was diluted in
twofold steps, showing parallelism with the standard curve.
Figure 2. A Western blot of rat tissue extracts (50 g per lane) resolved on 15% SDS-polyacrylamide gels, using the antibody (1 g/ml) to detect
myotrophin. A 12 kD band was evident in all extracts, with the lowest levels in spleen.
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RESULTS
A typical standard curve for myotrophin peptide is illus-
trated in Figure 1, showing a fall in chemiluminescence with
increasing concentrations of the peptide. Dilutions of pa-
tients’ plasma extracts showed parallelism with the standard
curve.
Figure 2 shows the reactivity of the antibody towards rat
tissue extracts, with a clear band detected in all tissues at 12
kD, the lowest expression being found in spleen. We also
localized myotrophin in human leucocytes using the
myotrophin antibody and goat horseradish peroxidase con-
jugated anti-rabbit IgG, with staining present entirely
within these cells.
Isocratic size exclusion chromatography was performed
on human plasma extracts (Fig. 3). This was resolved into
two main immunoreactive fractions, one at 12 kD (which is
the expected molecular weight of human myotrophin) and
another fraction at 2.7 kD, which is likely to be a degrada-
tion product consisting of the C-terminal of myotrophin (an
epitope to which the antiserum was directed).
The characteristics of the normal and HF patients are
shown in Table 1. Groups were well matched for age and
Figure 3. Size exclusion chromatography with analysis of the fractions for myotrophin. The points of elution of markers for 20 kD and 6.5 kD are indicated
by arrows. Two peaks of immunoreactivity for myotrophin are evident at 12 and 2.7 kD.
Table 1. Patient Characteristics in the Study
Normal Controls HF Patients p Value
Number 130 (41 [31%] female) 120 (35 [29%] female) NS for gender
Age (yrs) 60.4 (26–81) 63 (20–87) NS
Drug therapy None
Diuretics 98
Beta-blockers 47
ACE inhibitors 99
Etiology of cardiomyopathy
Ischemic 80
Dilated 29
Hypertensive 7
Valvular 4
NYHA class
I 29
II 34
III 30
IV 27
Medians (ranges) are reported, and p values were computed using analysis of variance (comparing normal and HF patients).
ACE  angiotensin-converting enzyme; HF  heart failure; NYHA  New York Heart Association.
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gender. In the normal population, there were no significant
gender differences in plasma myotrophin levels (Fig. 4), and
there was no correlation of myotrophin with increasing age.
In patients with HF, plasma myotrophin levels were very
significantly elevated (p  0.0005 by ANOVA). Homoge-
neity of variance was confirmed on all comparisons. Using
the univariate general linear model procedure with log
myotrophin as the dependent variable, and gender and
presence of HF as predictor variables, male gender (mean
SEM log myotrophin [geometric mean, range] in males
2.382  0.016 [241, 28 to 933] vs. females 2.288  0.024
[194, 81 to 537] fmol/ml, p  0.001) and presence of HF
(mean  SEM [geometric mean, range] HF 2.402  0.021
[252, 72 to 933] vs. normal 2.268  0.021 [185, 28 to 501]
fmol/ml, p  0.0005) were significant as predictors. There
was also a gender/presence of HF interaction (p  0.007)
suggesting that the plasma myotrophin response in males
with HF is different to that in females (Fig. 4). The adjusted
r2 for this model was 0.174. There was no significant
relationship of myotrophin with plasma creatinine levels.
The most common etiologies for HF were ischemic and
dilated cardiomyopathy, and, for both, log myotrophin
levels were significantly higher than normal controls (mean
 SEM [geometric mean, range], ischemic cardiomyopathy
2.443  0.023 [277, 83 to 933], dilated cardiomyopathy
2.479  0.034 [301, 81 to 691] fmol/ml, both p  0.0005
compared with normal controls). There was no significant
difference in myotrophin levels between the two etiologies.
Considering the predictors of log myotrophin levels in
the HF patients, we found that gender (p  0.0005) and
New York Heart Association (NYHA) class (p  0.001)
were significant contributors to the variance, r2 for this
model being 0.198. Males had higher levels than females (p
 0.001, Fig. 5), and myotrophin levels fell with increasing
NYHA class (NYHA I vs. NYHA IV, p  0.005; NYHA
II vs. NYHA IV, p  0.002 by Bonferonni’s test) (Fig. 5).
Myotrophin levels were not affected by therapy with diuret-
ics, angiotensin-converting enzyme inhibitors, or beta-
blockers. Similarly, stepwise linear regression analysis for
predicting log myotrophin levels using age, gender, and
NYHA class as independent variables confirmed gender and
NYHA class (standardized  coefficients 0.318 and
0.275, respectively, p  0.001 for both) as significant
predictors.
DISCUSSION
This is the first report documenting the presence of myotro-
phin in human plasma and describing an increased level in
the plasma of patients with HF. The specificity of our
in-house antibody was demonstrated by blotting tissue
extracts from a variety of rat organs, demonstrating the
ubiquitous presence of myotrophin. Myotrophin in human
plasma appears to be in two forms, one the full-length
myotrophin and the other a C-terminal fragment that is
Figure 4. Box plot of log-transformed plasma myotrophin levels in normal subjects and HF patients of both genders. Hatched bars  male; open bars
 female.
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likely to be a degradation product. Immunoassay of extracts
would detect both forms.
There is a clear gender difference in myotrophin plasma
levels in HF, with higher concentrations in males. In
addition, as the severity of the condition progresses, there is
a reduction in plasma myotrophin. From the current inves-
tigation, it is unclear whether changes in plasma myotro-
phin are due to differences in secretion or in clearance of the
peptide, although altered clearance is unlikely in view of the
observed fall in plasma levels with increasing HF severity.
Previous work on a limited number of cardiomyopathic
hearts suggests increased myocardial synthesis of the peptide
in HF (2,10). Human myotrophin RNA is widely distrib-
uted, being found in a wide variety of tissues including heart
and skeletal muscle, liver, pancreas, and other cardiovascular
tissue such as endothelial and vascular smooth muscle cells
(10). All of these tissues could be potential sources of
myotrophin, and it is uncertain which tissues contribute
towards circulating myotrophin, and whether the peptide is
actively secreted or leaking from damaged cells. The differ-
ence in response between males and females with HF is
striking, as is the fall in plasma levels with disease severity.
This paradoxical response of myotrophin may suggest that
at least some of the peptide could have an extra-cardiac
origin.
With regard to the latter point, it remains to be estab-
lished whether myotrophin levels influence prognosis or
degree of cachexia. Myotrophin has also been suggested to
be an NFB binding protein (5,6). Its translocation from
cytoplasm to nucleus during cell activation is also consistent
with this role of modulating NFB transactivating function
(7,10). Activation of the NFB system is widely docu-
mented in HF (8,9); NFB mediates the induction of gene
programs transcribing proinflammatory factors such as leu-
cocyte adhesion molecules, cytokines, and chemokines such
as TNF (9), which may be important in the progression of
HF. Tumor necrosis factor- and myotrophin also mutually
induce the transcription of each other (7), although these
are acute effects demonstrated in vitro in the absence of
other factors that may induce TNF; TNF rises with
increasing HF severity, but its transcription is dependent on
other factors other than myotrophin. The effect of myotro-
phin on altering the balance from highly activating p65-p50
heterodimers to repressive p50 homodimers and less active
p65 homodimers suggests that it may overall reduce NFB-
activated DNA transcription (6). It is, therefore, of interest
that we found the highest myotrophin plasma levels in early
HF, perhaps suggesting an adaptive role in disrupting
NFB-mediated DNA transcription. As the disease
progresses, less myotrophin was found, which would permit
unopposed activation of TNF by other factors. Myotro-
phin, when administered extracellularly, also has undoubted
effects on protein synthesis and inducing early response
genes and cell hypertrophy (3,4,7). Whether this adaptive
Figure 5. Relationship of plasma myotrophin with severity of heart failure in males and females. Hatched bars  male; open bars  female. NYHA 
New York Heart Association.
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role is present in early HF but fails in later stages of the
disease remains to be established in prospective studies of
HF. Few hormones or cytokines show this paradoxical
response to disease severity, but another example is urocor-
tin, which is a stress-induced peptide capable of inducing
diuresis and natriuresis in HF (13) and which we have
demonstrated to fall with increasing disease severity (un-
published observations).
In conclusion, we have reported the elevation of a novel
cardiac hypertrophy-inducing factor myotrophin in the
plasma of patients with HF, particularly in males. Further
investigations are warranted to elucidate the relationship of
myotrophin to the status of the NFB transcription system
in HF patients at different stages of the disease and its
impact on progression of the disease.
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